Intellia TherapeuticsNASDAQ: NTLA

CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (nex-z, also known as NTLA-2001) in patients with transthyretin (ATTR) amyloidosis. Nex-z is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron.

Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month's drop is appropriately discounting NTLA-2002, investors should be encouraged that 3 Phase III trials will be engaged by year-end, representing multiple opportunities for substantial upside. Intellia's financial position is robust with $945 million in cash, enough to fund operations into late 2026.

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Lina Li - Senior Director of Investor Relations and Corporate Communications John Leonard - President & Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer Ed Dulac - Executive Vice President & Chief Financial Officer Conference Call Participants Rick Bienkowski - Cantor Fitzgerald Yanan Zhu - Wells Fargo Securities Joseph Thome - TD Cowen Maury Raycroft - Jefferies Dae Gon Ha - Stifel Jay Olson - Oppenheimer Silvan Tuerkcan - Citizens JMP William Pickering - Bernstein Operator Good morning and welcome to Intellia Therapeutics' Third Quarter 2024 Financial Results Conference Call. My name is Drew and I will be your conference operator today.

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the third quarter ended September 30, 2024.

There's nothing bearish at all about what it reported recently.

Seemingly encouraging results from the lab were met with some notable skepticism.

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Call to Discuss NTLA-2002 Phase 2 Study Results Call October 24, 2024 11:00 AM ET Company Participants Lina Li - Senior Director, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer. Danny Cohn - Internist, Department of Vascular Medicine, Amsterdam University Medical Center Paula Busse - Professor of Medicine, Division of Clinical Immunology Jim Butler - General Manager, NTLA-2002 Program, Conference Call Participants Luca Issi - RBC Maury Raycroft - Jefferies Mani Foroohar - Leerink Partners Chris Yu - Morgan Stanley Gena Wang - Barclays Dae Gon Ha - Stifel Kostas Biliouris - BMO Capital Markets Rick Bienkowski - Cantor Fitzgerald William Pickering - Bernstein Ray Forset - Guggenheim Timur Ivannikovon - Raymond James Jay Olson - Oppenheimer Operator Good morning, and welcome to the Intellia Therapeutics Investor Event.

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.

- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at  8:30 a.m. ET